series-b
Stage
2024
Founded
1
Investors
About
GondolaBio is a clinical-stage biopharmaceutical company developing oral small molecule therapeutics targeting rare genetic diseases, including erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP), aiming to create disease-modifying treatments.
Explore GondolaBio's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.